CD274 and neoplasm: In ICI therapy, monoclonal antibodies against PD-1/PD-L1 and CTLA-4/CD80/86, are used to reverse the inhibitory effects of immune checkpoint proteins and enable anti-tumour responses in particular immune privilege [89, 90].